Page 4 - Skye Bioscience News Today

Skye Bioscience, Inc. (OTCMKTS:SKYE – Get Free Report) was the target of a large growth in short interest in the month of July. As of July 31st, there was short interest totalling 45,100 shares, a growth of 14.2% from the July 15th total of 39,500 shares. Based on an average trading volume of 2,376,800 shares, […]

Skye Bioscience, Inc. (OTCMKTS:SKYE – Get Free Report) was the target of a large decline in short interest in June. As of June 30th, there was short interest totalling 24,200 shares, a decline of 80.3% from the June 15th total of 123,100 shares. Based on an average trading volume of 2,567,100 shares, the short-interest ratio […]

(2023-07-06 | OTCQB:SKYE) Skye Bioscience Completes Production and Filling of Investigational Drug Material in Preparation for Phase 2a Glaucoma Clinical Trial

Skye Bioscience, Inc. SKYE, a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma and ocular hypertension,…

Skye Bioscience, Inc. (OTCQB: SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma and ocular hypertension, announced that its contract manufacturer, NextPharma Oy, in Finland, has completed production of placebo and

Penny stocks have long been known for their potential to deliver substantial gains, and identifying breakout opportunities within this market can be rewarding. Today, we delve into the realm of penny stocks, focusing on

Nabriva Therapeutics (NASDAQ:NBRV – Get Rating) and Skye Bioscience (OTCMKTS:SKYE – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations and earnings. Profitability This table compares Nabriva Therapeutics and Skye Bioscience’s […]

Skye completes dosing of final cohort of healthy volunteers in study of first-and-only-in-class proprietary cannabinoid derivativeSan Diego, Calif...

Skye plans to complete enrollment of Phase 1 study in June San Diego, California--(Newsfile Corp. - June 2, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company

Skye Bioscience (OTCMKTS:SKYE – Get Rating) and Arcturus Therapeutics (NASDAQ:ARCT – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation. Profitability This table compares Skye Bioscience and Arcturus Therapeutics’ […]